SGK1 inhibition attenuated the action potential duration in patient- and genotype-specific re-engineered heart cells with congenital long QT syndrome

BACKGROUND: Long QT syndrome (LQTS) stems from pathogenic variants in KCNQ1 (LQT1), KCNH2 (LQT2), or SCN5A (LQT3) and is characterized by action potential duration (APD) prolongation. Inhibition of serum and glucocorticoid regulated kinase-1 (SGK1) is proposed as a novel therapeutic for LQTS. OBJECT...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Maengjo, Das, Saumya, Tester, David J., Pradhananga, Sabindra, Hamrick, Samantha K., Gao, Xiaozhi, Srinivasan, Dinesh, Sager, Philip T., Ackerman, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Experimental
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134391/
https://www.ncbi.nlm.nih.gov/pubmed/37124559
http://dx.doi.org/10.1016/j.hroo.2023.02.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134391/
https://www.ncbi.nlm.nih.gov/pubmed/37124559
http://dx.doi.org/10.1016/j.hroo.2023.02.003

Ejemplares similares